Scientific deep-dive

Burping, Reflux and Gas on a GLP-1: The Label's Widest Gap

Eructation runs under 1% on placebo against 7% on Wegovy: a sevenfold difference, and the widest relative gap in the adverse-reactions table. Reflux is a much smaller increase than people expect.

By Ruth Calder · Enforcement Editor
Editorially reviewed (not clinically reviewed). Not medical advice · How we verify contentLast reviewed
6 min read·3 citations

Nausea gets the warnings. Burping does not, and it has the widest relative gap in the entire adverse-reactions table: under 1% on placebo against 7% on Wegovy.[1] That is a sevenfold difference, where nausea — the effect everyone is told about — is under threefold. If you started one of these and found yourself burping in a way you never did before, that is the drug, it is in the label, and nobody mentioned it.

The numbers, side by side

Upper-gut effects in the adult weight-management trials. Wegovy 2.4 mg against placebo (N=2,116).
EffectPlaceboWegovyRelative gap
Eructation (burping)<1%7%More than sevenfold
Dyspepsia (indigestion)3%9%Threefold
Abdominal distension (bloating)5%7%Modest
Flatulence4%6%Modest
Gastroesophageal reflux3%5%Modest

Reflux is worth separating from the rest. At 5% against 3% it is a real but modest increase — considerably less dramatic than the burping figure, and less than many people expect given how much is written about it.

Why it happens: the usual explanation, and its limits

The labels say these drugs delay stomach emptying, and the usual explanation runs from there: food that stays in the stomach longer has more time to produce gas, and puts more pressure below the valve that is supposed to keep stomach contents down. It is a plausible account, not a proven one. The authors of the pooled STEP analysis describe the cause of the stomach side effects as uncertain, note that the longer-acting drugs do not appear to delay emptying much, and point to a 20-week study of semaglutide 2.4 mg that found no measurable delay.[3]

The sulfurous smell many people describe is real enough, but no study has measured what causes it on these drugs. The common explanation is that food fermenting for longer produces sulfur-containing gases that the burping brings up. It is unpleasant, and on its own it is not one of the warning signs the labels list.

The likeliest common thread in that table is food moving through more slowly, though for the weekly drugs that has not been proven.

The dose question, which Zepbound's label answers

Wegovy’s table gives one dose against placebo. Zepbound’s is stratified across 5, 10 and 15 mg, which lets you see whether these effects climb with dose.[2] Mostly, they do not.

Zepbound, by dose. Placebo / 5 mg / 10 mg / 15 mg.
EffectPlacebo5 mg10 mg15 mg
Eructation1%4%5%5%
Gastroesophageal reflux2%4%4%5%
Dyspepsia4%9%9%10%

Each of these roughly doubles or triples from placebo to the lowest dose and then flattens. That is a different pattern from fatigue, which keeps climbing with dose. Practically, it means the burping you get at 5 mg is roughly the burping you get at 15 — so if you can tolerate it early, escalation is unlikely to make this specific problem much worse.

What actually helps

There are no trials of remedies for this, so what follows is mechanism-led and modest. It is worth saying plainly rather than dressing up.

  • Smaller meals, eaten more slowly. A stomach that empties slowly copes badly with volume, and swallowed air makes burping worse.
  • Carbonated drinks add gas to a system already holding it. Cutting them is the single change most people notice.
  • Fatty and very large meals sit longest. They also drive reflux independently.
  • Do not lie down after eating, which is standard reflux advice and matters more when the stomach is emptying slowly.
Reflux worth raising rather than managing. Persistent heartburn, pain on swallowing, food sticking, vomiting that will not settle, or black stools are not this. Long-running untreated reflux damages the esophagus, and a drug that slows gastric emptying is a reason to take it more seriously rather than less. This is also worth mentioning before any procedure with sedation — see holding a GLP-1 before endoscopy. Stomach pain rather than burning is a separate question, and GLP-1 stomach pain: what is expected and what is a warning sign sets out the patterns the labels single out.

For the effects further down the same system, our constipation guide covers what the labels report and what the evidence supports, and how long side effects last covers the escalation-week pattern most of them follow.

Frequently Asked Questions

The usual explanation is that the drug slows the stomach, so food sits longer and produces more gas, although that has not been proven for the weekly drugs. The label puts eructation at under 1% on placebo against 7% on Wegovy — a sevenfold difference, and the widest relative gap in the whole adverse-reactions table.
No study has measured it on these drugs. The usual explanation is that food staying longer in the stomach produces sulfur-containing gases, which burping brings up. On its own it is not one of the warning signs the labels list; stomach pain that is severe or will not go away is, and is covered in our guide to GLP-1 stomach pain.
Modestly. The Wegovy label reports gastroesophageal reflux in 5% against 3% on placebo, and Zepbound's dose-stratified table runs 2% on placebo against 4–5% across its doses. Real, but a much smaller increase than the burping figure and smaller than many people expect.
Probably not much. Zepbound's table shows these effects roughly doubling or tripling from placebo to the lowest dose and then flattening — eructation 4%, 5%, 5% across 5, 10 and 15 mg. That differs from fatigue, which keeps climbing.
Persistent heartburn, pain on swallowing, a sense of food sticking, vomiting that will not settle, or black stools. Long-running untreated reflux damages the esophagus, and it is also worth flagging before any procedure involving sedation.

References

  1. 1.Novo Nordisk Inc. WEGOVY (semaglutide) — US Prescribing Information, Section 6.1 Adverse Reactions: eructation, dyspepsia, abdominal distension, flatulence and gastroesophageal reflux disease (revised 06/2026) DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  2. 2.Eli Lilly and Company. ZEPBOUND (tirzepatide) — US Prescribing Information, Section 6.1 Adverse Reactions, dose-stratified table (SPL effective 2026-04-22) DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  3. 3.Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss Diabetes, Obesity and Metabolism. 2022. PMID: 34514682.

Constipation on a GLP-1: What the Labels Report and What Actually Helps

The Wegovy label reports constipation in 24% against 11% on placebo; the Zepbound label reports it by dose. Here is why it outlasts the nausea, and where the confident advice online runs ahead of the evidence.

6 min read

Dizzy on a GLP-1? The Blood-Pressure Question the Labels Skip

Dizziness affects 4% to 8% of people on the weight-loss doses. The labels tell prescribers to lower insulin or sulfonylurea doses, and say nothing about blood-pressure pills, though low blood pressure is more common in people taking them.

7 min read

GLP-1 Diarrhea: Why It Doesn't Follow the Dose, and What Has Actually Been Tested

Diarrhea affects 19% to 30% of people on the weight-loss doses. Unlike nausea and vomiting, it stayed flat when semaglutide was tripled and was identical in the tirzepatide vs semaglutide trial. No treatment for it has ever been tested.

9 min read

Injection Site Reactions: Where Semaglutide and Tirzepatide Really Differ

Semaglutide produced injection site reactions in 1.4% against 1% on placebo. Tirzepatide runs 6–8% against 2%. If you react on one and not the other, that is not your technique.

5 min read

Joint Pain, Back Pain and Aches on a GLP-1: What the Trials Counted

No FDA label for these drugs lists joint or back pain, and in most trials both were about as common on placebo. The exception is the 7.2 mg Wegovy trial, and the one pain the labels do list is in the skin.

8 min read

Semaglutide Week by Week: When the Weight Actually Comes Off

The starting dose is not a treatment dose. In the trial that measured the climb, participants spent 20 weeks reaching full strength. Here is what the STEP trials recorded at each stage, and what came back after stopping.

7 min read

Where to get tirzepatide (Mounjaro / Zepbound) online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

6.7

RxSpan MD

Knowing which pharmacy fills the vial: it names Belmar Pharmacy

8.3

SnagRx

Semaglutide at $99/month, 48% below the typical price

9.3

Embody

Knowing which pharmacy fills the vial: it names RedRock Pharmacy